Dr. Deborah Dunsire
Next up, EnVivo Pharmaceuticals welcomes Dr. Deborah Dunsire as its new President and CEO.
She joins the firm that specializes in finding novel therapies for CNS related diseases following eight years of being CEO at Millennium Pharmaceuticals, acquired in 2008 by Takeda in 2008 for $8.8bn.
Chairman of the Board, Dr. Stephen Knight praised Dunsire and said: “She joins EnVivo at a transformative point in the company’s evolution, as our lead product, EVP-6124, is in Phase 3 clinical trials in schizophrenia and will enter a Phase 3 clinical trial in Alzheimer’s disease later this year.”